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Introduction: High pulmonary artery flow rates can result in severe reperfusion
injury after lung transplantation. Our hypothesis was that selective activation of the
adenosine A2A receptor with a highly specific analog (ATL-146e) would inhibit
leukocyte activation and decrease reperfusion injury after high-flow reperfusion.
Methods: Using our isolated, ventilated, blood-perfused rabbit lung model, all
groups (n 8 per group) underwent lung harvest, 4 hours of cold storage, and blood
reperfusion for 30 minutes. Measurements of pulmonary artery pressure (in milli-
meters of mercury), arterial oxygenation (in millimeters of mercury), myeloperox-
idase, peak inspiratory pressure, and wet/dry weight ratio were obtained. Groups 1
(high flow) and 2 (high flow ATL-146e) underwent reperfusion at 120 mL/min for
30 minutes. Groups 3 (controlled high flow) and 4 (controlled high flow ATL-146e)
underwent controlled reperfusion with an initial reperfusion of 60 mL/min for the
first 5 minutes, followed by a rate of 120 mL/min for 25 minutes. During reperfu-
sion, groups 2 and 4 received ATL-146e at 4 g  kg1  min1.
Results: ATL-146e significantly improved lung physiologic measurements under
both high-flow (group 1 vs group 2) and controlled high-flow (group 3 vs group 4)
conditions after 30 minutes.
Conclusions: The adenosine A2A receptor analogue ATL-146e significantly de-
creases the severity of reperfusion injury in the setting of both high-flow and
controlled high-flow reperfusion.
Despite improvements in lung transplantation, transplanted lungsremain vulnerable to ischemia-reperfusion injury, with severegraft dysfunction occurring in 20% of lung transplant recipi-ents.1,2 Although severe graft dysfunction can be reversible, it isoften associated with the need for prolonged intensive care andincreased mortality.3,4 It has become increasingly evident that
reperfusion is responsible for the majority of tissue injury after lung transplanta-
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tion.5 Additionally, some investigators have suggested that
high pulmonary artery flow rates increase the risk of severe
reperfusion injury after lung transplantation. In our clinical
practice, patients with preexisting pulmonary hypertension
are at increased risk for reperfusion injury.6 Other authors
have also shown that a more severe reperfusion injury
seems to occur in these patients as well.7-9 The increased
risk for reperfusion injury in these patients might be the
result of activation of the inflammatory cascade against
endothelium that is damaged as a result of the high-flow
state. Our hypothesis was that selective activation of the
adenosine A2A receptor with a highly specific analogue
(ATL-146e) would inhibit leukocyte activation and de-
crease reperfusion injury after high-flow reperfusion.
Materials and Methods
Experimental Protocol
Using our isolated, ventilated, blood-perfused rabbit lung model,
all groups (n  8 per group) underwent lung harvest, 4 hours of
cold storage, and blood reperfusion for 30 minutes. Groups 1 (high
flow) and 2 (high flow ATL) underwent reperfusion at 120 mL/min
for 30 minutes. Groups 3 (controlled high flow) and 4 (controlled
high flow ATL) underwent controlled reperfusion with an initial
reperfusion rate of 60 mL/min for the first 5 minutes, followed by
a rate of 120 mL/min for 25 minutes. During reperfusion, groups
2 and 4 received ATL-146e at 4 g  kg1  min1. This dose was
selected after a preliminary experiment with doses of ATL-146e at
0.01, 0.1, 1.0, and 4.0 g  kg1  min1.
Harvest Procedure
Adult New Zealand White rabbits of both sexes weighing 3.0 to
3.5 kg were randomly assigned to the 3 experimental groups.
Animals were anesthetized with intramuscular ketamine (50 mg/
kg) and xylazine (5 mg/kg). Tracheal intubation was performed
through a tracheostomy, and mechanical ventilation was instituted
with a constant pressure ventilator (#RSP1002; Kent Scientific
Corp, Litchfield, Conn) with room air at a rate of 18 breaths/min.
A median sternotomy and thymectomy were then performed. The
2 superior and 1 inferior venae cavae were loosely encircled with
ligatures, and the pericardium was opened. Both the pulmonary
artery (PA) and aorta were dissected free and similarly encircled.
A purse-string suture was placed in the free wall of the right
ventricle, and intravenous heparin was administered (500 U/kg).
After injection of 30 g of alprostadil (prostaglandin E1; Upjohn
Company, Kalamazoo, Mich) into the PA, the cavae were inter-
rupted, and onset of ischemia was noted. The PA was then can-
nulated through a right ventriculotomy placed in the center of the
purse-string suture. Both the right ventricle and PA ligatures were
tied to secure the cannula. After venting the left ventricle with a
left ventriculotomy and ligating the aorta, 50 mL/kg Euro-Collins
(Hamburg, Germany) preservation solution was infused at 4°C
into the PA from a height of 30 cm. Topical cooling was achieved
with cold saline solution slush. During the PA flush, the left atrium
was cannulated through the left ventriculotomy with an outflow
catheter and a catheter to directly transduce left atrial pressures. A
purse-string suture was placed to secure these cannulas. After
completion of the PA flush, the inflow and outflow cannulas were
clamped. The heart-lung block was then excised, and the trache-
ostomy tube was clamped at end inspiration. The inflated lungs
were stored immersed in saline solution at 4°C for 4 hours. All
animals received humane care in compliance with the “Guide for
the Care and Use of Laboratory Animals,” published by the Na-
tional Institutes of Health (National Institutes of Health publication
No. 85-23, revised 1996).
Reperfusion Procedure
After organ harvest and ischemic storage, the heart-lung block was
suspended in a warm, humidified tissue chamber, and ventilation
was reestablished with a 95% oxygen and 5% carbon dioxide gas
Figure 1. Isolated, blood-perfused rabbit lung model: diagram of the isolated lung model. P, Pressure transducer;
N2, nitrogen gas; O2, oxygen gas.
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mixture at a respiratory rate of 18 breaths/min by using the
constant pressure ventilator (Figure 1). The inflow and outflow
cannulas were then connected to a venous blood reperfusion cir-
cuit. New Zealand White rabbits weighing 3.5 to 5.0 kg served as
fresh venous blood donors. The lungs were reperfused with venous
blood from a main reservoir. A second nonrecirculated venous
blood reservoir was used to challenge the lungs and to determine
the single-pass oxygenation values during reperfusion. The circuit
(Kent Scientific Corp) was designed to recirculate 150 mL of
warmed blood with a roller pump (#7521-40; Cole Palmer Instru-
ment Co, Chicago, Ill).
Continuous recordings of pulmonary artery pressure (PAP), left
atrial pressure, and air flow were performed with a dynamic
data-acquisition program (Workbench PC; Strawberry Tree, Inc,
Sunnydale, Calif) on a personal computer (#470A; Compaq Pro-
linea, Houston, Tex). This program automatically calculated and
displayed tidal volume, pulmonary vascular resistance, and dy-
namic airway compliance. Pulmonary venous blood samples were
collected for blood gas analysis (Corning 178pH/Blood Gas An-
alyzer; Corning Inc, Corning, NY) after 10, 20, and 30 minutes of
reperfusion. At each sampling interval, inflow from the main
reservoir was temporarily interrupted, and the circuit was filled
with nonrecirculated blood from the second inflow reservoir. A
30-mL sample of venous blood was passed through the pulmonary
vasculature at each interval to obtain accurate measurements of
pulmonary venous oxygen content. Oxygen contact with exposed
blood surfaces was minimized by means of continuous passive
infusion of 100% nitrogen.
Lung Wet/Dry Weight Ratios
Lung wet/dry weight ratios were used as a measurement of pul-
monary edema. Samples of lung tissue were weighed immediately
after reperfusion. These samples then underwent passive desicca-
tion at room temperature until a stable dry weight was achieved.
The weight immediately after reperfusion and the stable dry
weight were then used to calculate the lung wet/dry weight ratios.
Lung Tissue Myeloperoxidase
A myeloperoxidase assay was performed to quantify neutrophil
sequestration. Lung tissue was placed in 5 mL of 0.5% hexade-
cyltrimethyl-ammonium bromide in 50 mmol/L potassium phos-
phate solution (pH 7.4) and disrupted by means of homogenizing
at 4°C. The solution was centrifuged at 15,000g for 15 minutes at
4°C, and the supernatant was discarded. The pellet was resus-
pended in 2 mL of 0.5% hexadecyltrimethyl-ammonium bromide
in 50 mmol/L potassium phosphate solution (pH 6.0) and homog-
enized. Tissue was disrupted further by means of ultrasonication
and 3 freeze-thaw cycles (liquid nitrogen bath/37°C water bath).
The solution was again centrifuged at 15,000g for 15 minutes at
4°C. Aliquots (0.1 mL) of supernatant were added to the assay
buffer of o-dianisdine dihydrochloride, H2O2, and 50 mmol/L
potassium phosphate (pH 6.0). Absorbance at 460 nm was mea-
sured over 2 minutes by means of spectrophotometry (LKB Model
4050, Cambridge, England). Lung tissue myeloperoxidase activity
was expressed as the change in absorbance per milligram of dry
weight per minute.
Figure 2. Arterial oxygenation. The high-flow ATL group (High-ATL) had significantly improved arterial oxygenation
after 30 minutes of reperfusion compared with that of the high-flow (High) group. Similarly, the controlled high-flow
ATL (CP-ATL) group had significantly improved arterial oxygenation compared with that of the controlled high-flow
(CP) group. *P  .002, high-flow ATL group versus high-flow group; **P  .004, controlled high-flow group ATL
versus controlled high-flow group.
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Statistical Analysis
Statistical analysis was performed by using analysis of variance on
SPSS software (SPSS Inc, Chicago, Ill). Significant differences
were determined by using the Tukey significant difference test.
Data are expressed as means  SD.
Results
Physiologic Measurements
The high-flow ATL group (73.4  22.0 mm Hg, P  .002,
Figure 2) had significantly improved arterial oxygenation
measurements compared with those of the high-flow group
(41.0  11.7 mm Hg) after 30 minutes of reperfusion.
Similarly, the controlled high-flow ATL group (123.6 
19.7 mm Hg, P  .004) had significantly improved arterial
oxygenation measurements compared with those of the
high-flow group (87.0  27.5 mm Hg) after 30 minutes of
reperfusion.
PAP was significantly lower in the high-flow ATL group
(66.0 7.4 mm Hg, P .015, Figure 3) compared with that
of the high-flow group (80.1  12.3 mm Hg). Similarly, the
controlled high-flow ATL (50.3  6.4 mm Hg, P  .003)
group had significantly lower PAP measurements compared
with those of the controlled high-flow group (62.9  7.8
mm Hg) after 30 minutes of reperfusion.
There was a trend toward decreased peak airway pres-
sure in the high-flow ATL group (11.8  0.45 mm Hg, P 
.086) compared with that in the high-flow group (13.7 
0.57 mm Hg). There were no significant differences in peak
airway pressure in the controlled high-flow ATL group
(18.5  0.64 mm Hg, P  .29) compared with values in the
controlled high-flow group (19.5  0.68 mm Hg).
Lung Wet/Dry Weight Ratio
The wet/dry weight ratio was significantly lower in the
high-flow ATL group (11.8  1.28, P  .018) compared
with that in the high-flow group (13.7  1.62). Wet/dry
weight ratio was not significantly different between the
controlled high-flow ATL group (6.0 1.49, P .184) and
the controlled high-flow group (6.9  1.01).
Tissue Myeloperoxidase Assay
Myeloperoxidase activity was not significantly different be-
tween the high-flow (0.31  0.09 absorbance/mg dry
weight/min) and high-flow ATL groups (0.29  0.09 ab-
sorbance/mg dry weight/min). Similarly, myeloperoxidase
activity was not significantly different between the con-
trolled high-flow (0.22  0.08 absorbance/mg dry weight/
min) and controlled high-flow ATL (0.17  0.06 absor-
bance/mg dry weight/min) groups.
Discussion
Approximately 20% to 30% of all lung transplant recipients
experience reperfusion injury, which has an associated mor-
tality of 40% in some series.1,2 Although the exact mecha-
nism of this process has not been fully discerned, clinical
studies have suggested that certain patient populations, such
as patients with preexisting pulmonary hypertension, might
be at increased risk for reperfusion injury after lung trans-
Figure 3. Pulmonary artery pressure. The high-flow ATL group (High-ATL) had a significantly lower PAP compared
with that of the high-flow (High) group. Similarly, the controlled high-flow ATL (CP-ATL) group had significantly
improved PAP measurements compared with those of the controlled high-flow (CP) group. *P < .015, high-flow ATL
group versus high-flow group; **P < .003, controlled high-flow ATL group versus controlled high-flow group.
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plantation.7-9 In our own clinical practice, patients with
preexisting pulmonary hypertension are at increased risk of
reperfusion injury.6 A more severe reperfusion injury seems
to occur in patients with preexisting pulmonary hyperten-
sion as well.7-9 This patient population would include pa-
tients with primary pulmonary hypertension in addition to
patients with secondary pulmonary hypertension as a result
of congenital heart defects. Additionally, however, patients
undergoing lung transplantation for restrictive lung diseases
often have severe pulmonary hypertension as a result of
pulmonary fibrosis. Other authors, in addition to the present
ones, have shown an increased risk of reperfusion injury in
patients with restrictive lung disease.6,10
One possible mechanism by which those patients have
reperfusion injury is through mechanical disruption of the
pulmonary vascular endothelium. This would result in in-
creased pulmonary edema and lung dysfunction as a result
of the disrupted endothelium. Another possible mechanism
for the increased reperfusion injury seen in those patients is
through increased hydrostatic gradient created by increased
PAP, which might serve to drive fluid across endothelial
membranes. Additionally, endothelial disruption results in
collagen exposure, which might be serving to activate cir-
culating leukocytes against the transplanted lung. Many
studies have shown that circulating white blood cells are
one of the major mediators of reperfusion injury after lung
transplantation.11-15
One of the major anti-inflammatory mechanisms used by
endothelial cells is mediated through the release of adeno-
sine.2 Adenosine receptors are ubiquitous membrane recep-
tors found on many inflammatory cell types, including mac-
rophages and neutrophils.16-20 Activation of these receptors
results in suppression of the inflammatory function of these
cells. Adenosine has been shown to be a protective agent in
models of warm lung ischemia-reperfusion injury,21 cardiac
ischemia-reperfusion injury,22 intestinal reperfusion inju-
ry,23 and hepatic ischemia-reperfusion injury.24 Different
types of adenosine receptors exist (A1, A2A, A2B, and A3)
and have different functions. For example, the adenosine A1
receptor can have proinflammatory effects, including neu-
trophil chemotaxis and neutrophil adherence to endothelial
cells.22 To avoid these proinflammatory effects, we chose a
selective A2A receptor analogue. Adenosine receptor sub-
classification has shown specifically that activation of the
adenosine A2A receptor prevents leukocyte adhesion to en-
dothelial cells, as well as inhibiting the release of toxic
oxygen products.17
The present study demonstrates that leukocyte inhibition
with ATL-146, which is a highly potent and specific acti-
vator of the adenosine A2A receptor,25 results in improved
arterial oxygenation and PAP under both high-flow and
controlled high-flow reperfusion conditions. Additionally,
pulmonary edema, as assessed on the basis of wet/dry
weight ratio, was significantly lower in the high-flow ATL
group compared with in the high-flow group. These data
would suggest that the inflammatory cascade has a role in
reperfusion injury after high-flow reperfusion.
Interestingly, although myeloperoxidase activity was
lower in the high-flow ATL group compared with that in the
high-flow group and in the controlled perfusion ATL group
compared with that in the controlled perfusion group, these
comparisons did not reach statistical significance. Had the
experiment been carried out for a longer time period, the
gradual buildup of sequestered leukocytes might have
brought out more of a difference between the various
groups. Another possibility, however, is that the adenosine
analogue is acting on cells other than circulating leukocytes.
Previously, we have shown that circulating leukocytes are
not significantly involved in reperfusion injury until after 2
hours of reperfusion.15 Furthermore, our studies have also
suggested that intrinsic pulmonary macrophages might be
involved in the earliest phase of reperfusion injury after
lung transplantation.26 Alveolar macrophages, in addition to
circulating neutrophils, are known to carry the A2A receptor
and thus might be the initial key target for the A2A analogue.
Another possibility is that the A2A analogue was acting
directly on the pulmonary vasculature, leading to vasodila-
tion, although many studies have shown the action of this
drug is on white blood cells.16-20
One further observation in this study was the effect of
controlled perfusion on reperfusion injury. Controlled per-
fusion seemed to improve physiologic measurements com-
pared with high-flow reperfusion. Our group has previously
published on this topic.27
In summary, high-flow reperfusion can cause significant
lung dysfunction after lung transplantation. Adenosine A2A
receptor activation with ATL-146e significantly reduces
reperfusion injury associated with high-flow and controlled
high-flow conditions, possibly by inhibiting white blood
cells. Thus adenosine A2A agonists might have a future
clinical role in lung transplantation.
We thank Anthony Herring and Sheila Hammond for their
expert technical advice and support.
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Discussion
Dr Ralph A. Schmid (Berne, Switzerland). Why did you use
the Euro-Collins solution in these experiments? I think the era of
Euro-Collins is over.
Dr Fiser. We still use Euro-Collins at our institution.
Dr Schmid. Did you look at reperfusion for longer times than
30 minutes? This is a very short observation time, and therefore the
differences might not be significant.
Dr Fiser. No, we only looked at 30 minutes. I think our future
studies involving high-flow reperfusion should be carried out for
more extended time periods.
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